肿瘤细胞治疗研究
英文原题：Mucosal Melanoma: An Overview of Recent Therapies.
黏膜黑色素瘤（MM）是一种侵袭性疾病，在危险因素、预后和治疗方面与皮肤黑色素瘤不同。
黏膜黑色素瘤（MM）是一种侵袭性疾病，在危险因素、预后和治疗方面均不同于皮肤黑色素瘤。目前，手术是局限性疾病的首选治疗，但复发较常见。对于晚期或转移性疾病，PD-1抑制剂和抗CTLA-4免疫疗法通常作为一线治疗；然而，与皮肤黑色素瘤相比，MM对免疫治疗的总体应答率往往较低、应答不够持久。过继性TIL疗法显示出很大前景。其他进展，尤其是对新疗法和联合疗法的探索，为改善黏膜黑色素瘤患者结局带来了希望。本文综述MM当前治疗选择，并更新该患者群体可参与的未来临床试验。
Mucosal Melanoma (MM) is an aggressive disease that is distinct from cutaneous melanoma in risk factors, prognosis, and treatment. Surgical treatment is currently the treatment of choice for localized disease; however, the recurrence rate is common. For advanced or metastatic disease, immunotherapy with PD-1 inhibitors and anti-CTLA is generally first-line treatment, however the overall responses to immunotherapy in MM are often lower and less robust when compared to that observed in cutaneous melanoma. Adoptive-TIL therapy has shown great promise. Other advances, particularly through the exploration of novel and combination therapies, are a step forward and a hope to improve outcomes in patients with mucosal melanoma. In this review, we summarize current treatment options for MM, and we updated future clinical trials available for this population of patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
